title: Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months.
abstract: Improvements in overactive bladder (OAB) symptoms and health-related quality of life (HRQL) were assessed during a 24-week study of tolterodine extended release (TOL ER) in sexually active women with OAB and urgency urinary incontinence (UUI). A 12-week, double-blind, randomized, placebo-controlled trial was followed by a 12-week open-label phase. Sexually active women reported symptoms for >or=3 months. Subjects completed bladder diaries and HRQL measures at baseline and weeks 12 and 24. One hundred sixty-one women received TOL ER for 24 weeks. Women reported significant improvements in all end points at week 12 that were maintained or improved at 24 weeks. At week 24, 70% of subjects reported no UUI episodes. TOL ER resulted in improvements in OAB symptoms and HRQL that were maintained or greater with 6 months of use. Long-term compliance with OAB pharmacotherapy may be important for optimal treatment outcomes.
authors.affiliation: Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA. rrogers@salud.unm.edu
authors.forename: Rebecca G
authors.initials: RG
authors.lastname: Rogers
authors.forename: Tola
authors.initials: T
authors.lastname: Omotosho
authors.forename: Gloria
authors.initials: G
authors.lastname: Bachmann
authors.forename: Franklin
authors.initials: F
authors.lastname: Sun
authors.forename: Jon D
authors.initials: JD
authors.lastname: Morrow
mesh_terms: D000328:Adult; D001007:Anxiety; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D003408:Cresols / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003863:Depression; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006306:Health Surveys; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D012725:Sexual Behavior / Q000502:physiology / Q000523:psychology; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D053202:Urinary Incontinence, Urge / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate